Pre-emptive steroids for a severe oedematous Buruli ulcer lesion: a case report

Journal of Medical Case Reports

Sarah Huffam²  Daniel P O’Brien¹ 

[1] Manson Unit, Médecins Sans Frontières, 67-74 Saffron Street, London EC1N 8QX, UK;Department of Infectious Diseases, University Hospital, 292-392 Ryrie Street, Geelong 3220, VIC, Australia

关键词: Oedematous;    Antibiotics;    Treatment;    Prednisolone;    Buruli ulcer;    Mycobacterium ulcerans;   

Others  :  1204619
DOI  :  10.1186/s13256-015-0584-x

 received in 2014-10-17, accepted in 2015-02-21,  发布年份 2015

【 摘 要 】

Introduction

Severe oedematous forms of Buruli ulcer (BU) often result in extensive tissue destruction, even with the institution of appropriate antibiotic treatment, leading to reconstructive surgery and long-term disability. We report a case of a patient with severe oedematous BU, which describes for the first time the pre-emptive use of prednisolone therapy commenced at the time of antibiotic initiation aimed at limiting the ongoing tissue destruction and its secondary sequelae.

Case presentation

A 91-year-old Australian-born Caucasian woman presented with a WHO category 3 oedematous BU lesion on the anterior aspect of her right ankle that she had first noticed three weeks earlier. Treatment was commenced with an antibiotic combination of rifampicin and ciprofloxacin. At the same time, pre-emptive prednisolone was commenced (a dose of 0.5mg/kg daily). Treatment resulted in rapid and significant reduction in the size of the induration associated with the lesion, and no significant increase in the size of the skin ulceration. Antibiotics were continued for 56 days and prednisolone therapy ceased 130 days after antibiotics commenced. No surgery was required. The wound healed completely after 10 months and there was no long-term limitation of movement at the ankle joint.

Conclusions

Pre-emptive corticosteroid therapy may prevent further progressive tissue necrosis and the need for secondary reconstructive surgery that commonly occurs during the antibiotic treatment of severe odematous forms of BU.

【 授权许可】

   
2015 O'Brien and Huffam; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]O'Brien DP, Friedman ND, McDonald A, Callan P, Hughes A, Athan E. Clinical features and risk factors of oedematous Mycobacterium ulcerans lesions in an Australian population: beware cellulitis in an endemic area. PLoS Negl Trop Dis. 2014; 8: Article ID e2612
• [2]Phanzu DM, Ablordey A, Imposo DB, Lefevre L, Mahema RL, Suykerbuyk P et al.. Short report: edematous Mycobacterium ulcerans infection (Buruli ulcer) on the face: a case report. Am J Trop Med Hyg. 2007; 77:1099-102.
• [3]O'Brien DP, Jenkin G, Buntine J, Steffen CM, McDonald A, Horne S et al.. Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust. 2014; 200:267-70.
• [4]Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. World Health Organization, Geneva, Switzerland; 2012.
• [5]Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W et al.. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet. 2010; 375:664-72.
• [6]Friedman ND, Athan E, Hughes AJ, Khajehnoori M, McDonald A, Callan P et al.. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLoS Negl Trop Dis. 2013; 7: Article ID e2315
• [7]Jenkin GA, Smith M, Fairley M, Johnson PD. Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust. 2002; 176:180-1.
• [8]Pak J, O'Brien DP, Quek TY, Athan E. Treatment costs of Mycobacterium ulcerans in the antibiotic era. International Health. 2012; 4:123-7.
• [9]Stienstra Y, van Roest MH, van Wezel MJ, Wiersma IC, Hospers IC, Dijkstra PU et al.. Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Tropical Med Int Health. 2005; 10:1251-7.
• [10]Carvalho AC, De Iaco G, Saleri N, Pini A, Capone S, Manfrin M et al.. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis. 2006; 42:893-5.
• [11]O'Brien DP, Robson M, Friedman ND, Walton A, McDonald A, Callan P et al.. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis. 2013; 13:416. BioMed Central Full Text
• [12]Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF et al.. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013; 123:1501-12.
• [13]Friedman ND, McDonald A, Robson M, O'Brien DP. Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLoS Negl Trop Dis. 2012; 6: Article ID e1767
• [14]Wanda F, Nkemenang P, Ehounou G, Tchaton M, Comte E, Toutous Trellu L et al.. Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection. BMC Infect Dis. 2014; 14:423. BioMed Central Full Text
• [15]Martins TG, Trigo G, Fraga AG, Gama JB, Longatto-Filho A, Saraiva M et al.. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection. PLoS Negl Trop Dis. 2012; 6: Article ID e1925
• [16]O'Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, McDonald A et al.. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust. 2007; 186:58-61.
• [17]O'Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report. J Med Case Rep. 2008; 2:123. BioMed Central Full Text
• [18]O'Brien DP, McDonald A, Callan P, Robson M, Friedman ND, Hughes A et al.. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis. 2012; 6: Article ID e1473